PRA Health Sciences Late Phase Services is participating in a global real world safety study program, mandated by various regulatory bodies, to confirm risk/benefit profile for a novel oral anticoagulant to assess the drug’s bleeding risk. Our ability to provide global operational oversight and efficiencies, ensure consistent communication with sites, and keep our patients engaged resulted in PRA becoming the client’s CRO of choice.
PRA INSIGHTS REPORT 2018 ISPOR-North America Survey Results
A summary of survey results from ISPOR’s Annual North America meeting, where we gathered insights on important developments in the real world…
THE INSIGHT SERIES: Why do prescribers participate? - Part III
While Phase II-III studies include small datasets, comprising several hundred to several thousand patients, they provide the data necessary for drug…
Join PRA in China
The expertise of a global CRO + local know-how to deliver the highest caliber of clinical development services around the world.